Calls for papers
-
University of California, San Francisco spinout Aer Therapeutics has closed a $36 million Series A financing, with funds intended to support development of the company’s AER-01 inhaled mucolytic for the treatment of COPD, the company… Read more . . .
-
US-based startup Pocket Naloxone said that a human factors study of its NaxSwab OTC naloxone nasal swab demonstrated that the swab could be used effectively in a simulated emergency by a wide range of people,… Read more . . .
-
Tiziana Life Sciences has announced that the company will develop intranasal foralumab for the treatment of long COVID. In August 2021, Tiziana announced positive results from a pilot study of intranasal foralumab in mild-to-moderate COVID.… Read more . . .
-
HCmed Innovations announced that former AstraZeneca Science and Innovation Director of Inhaled Drug Delivery Gunilla Petersson has joined the company as Chief Scientific Officer. Petersson has almost 30 years of experience in the pharmaceutical industry, primarily… Read more . . .
-
According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent that will protect the company’s Gimoti metaclopramide nasal spray until 2030. The patent (No.… Read more . . .
-
Nuance Pharma has initiated the ENHANCE – China Phase 3 study of nebulized ensifentrine in mainland China, the company said. Nuance obtained the rights to develop and market ensifentrine in China, Macau, Taiwan, and Hong Kong… Read more . . .
-
Former Arranta Bio CEO David Stevens has joined CDMO Kindeva Drug Delivery as Chief Commercial Officer, the company said. Prior to Arranta, Stevens held a variety of roles at Albany Molecular Research, Aptuit, and Charles… Read more . . .
-
Tiziana Life Sciences announced that it will advance its intranasal foralumab anti-CD3 monoclonal antibody into clinical development for the treatment of hemorrhagic stroke after a pre-clinical study in a model of intracerebral hemorrhage demonstrated improvement… Read more . . .
-
Liquidia Corporation said that a new agreement will supersede its 2012 license agreement with GSK that gave GSK exclusive rights to develop certain inhaled formulations based on Liquidia’s PRINT particle engineering technology. In 2015, GSK exercised… Read more . . .
-
Orexo announced that the FDA will require the company to resubmit its NDA for OX124 intranasal dry powder naloxone due to “unexpected technical issues with the equipment used for the secondary packaging process in the… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland